T1	Participants 63 104	acquired nystagmus in multiple sclerosis:
T2	Participants 185 217	patients with multiple sclerosis
T3	Participants 802 850	eight patients with definite multiple sclerosis.
T4	Participants 1231 1294	Three out of eight patients dropped out due to adverse effects.
T5	Participants 1406 1460	Three patients decided to continue gabapentin therapy.
